Skip to content

Probiotics Regulates Skin Care in Children

Probiotics Regulates Skin Care in Children : A Randomized, Double-blind Clinical Trial With Placebo

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05005611
Enrollment
148
Registered
2021-08-13
Start date
2021-05-31
Completion date
2024-12-31
Last updated
2023-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Probiotics, Skin Care

Brief summary

Probiotics, a component that is generally referred to as a living microorganism or a microorganism present in a host. Most studies have shown that probiotics can regulate immune function in the body. Many studies have attempted to understand whether the use of probiotics can prevent allergic diseases or not.

Interventions

DIETARY_SUPPLEMENTPlacebo

A pack of powder without probiotics. 1 pack / day

DIETARY_SUPPLEMENTProbiotics Lactobacillus salivarius AP-32

A pack of powder with probiotics Lactobacillus salivarius AP-32 1 pack / day

DIETARY_SUPPLEMENTProbiotics Bifidobacterium animalis subsp. lactis CP-9

A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9 1 pack / day

DIETARY_SUPPLEMENTProbiotics Lactobacillus rhamnosus LGG

A pack of powder with probiotics Lactobacillus rhamnosus LGG 1 pack / day

Sponsors

Glac Biotech Co., Ltd
CollaboratorINDUSTRY
Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Masking description

Double-blind.

Intervention model description

Skin Care in children.

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Estimated by PI.

Exclusion criteria

* Be allergic to medicine * Take medicine like immune inhibition, or steroid injection in two weeks * Participate in another clinical research or immune therapy in one month * Have severe disease * Inappropriate for this trial judged by PI

Design outcomes

Primary

MeasureTime frameDescription
Skin severity scoring3 monthsAccording to the scale to estimate skin severity

Secondary

MeasureTime frameDescription
Blood analysis3 monthsELISA analysis
NGS in gastrointestinal tract3 monthsThe difference of NGS ( Next Generation Sequence ) in gastrointestinal tract between 0 month and the 3rd month.
Life quality3 monthsThe questionnaire of life quality in three months.

Countries

Taiwan

Contacts

Primary ContactKuo Ho-Chang
erickuo48@yahoo.com.tw(07)7317123

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026